# Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

> **NCT01136161** · PHASE2 · COMPLETED · sponsor: **Archivel Farma S.L.** · enrollment: 95 (actual)

## Conditions studied

- Latent Tuberculosis Infection
- Tuberculosis

## Interventions

- **BIOLOGICAL:** RUTI
- **BIOLOGICAL:** RUTI
- **BIOLOGICAL:** RUTI
- **BIOLOGICAL:** RUTI Matching Placebo

## Key facts

- **NCT ID:** NCT01136161
- **Lead sponsor:** Archivel Farma S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2013-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01136161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01136161, "Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01136161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*